Information Provided By:
Fly News Breaks for May 13, 2019
May 13, 2019 | 09:25 EDT
B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $26 from $19 citing increased visibility into the company's three "high-value" cardio targets. The analyst sees "significant optionality" in Arrowhead's pipeline and he keeps a Buy rating on the shares. The analyst added ARO-APOC3 and ARO-ANG3 to his model, albeit with low probability of success given still the early stage of development. He keeps a Buy rating on the shares.
News For ARWR From the Last 2 Days
There are no results for your query ARWR